Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Public ClinicalTrials.gov record NCT02231749. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Study identification
- NCT ID
- NCT02231749
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 1,096 participants
Conditions and interventions
Interventions
- Nivolumab Biological
- Ipilimumab Biological
- Sunitinib Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2014
- Primary completion
- Jun 25, 2017
- Completion
- Mar 20, 2025
- Last update posted
- May 26, 2026
2014 – 2025
United States locations
- U.S. sites
- 37
- U.S. states
- 20
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0006 | Duarte | California | 91010 | — |
| Local Institution - 0057 | La Jolla | California | 92093-0698 | — |
| Local Institution - 0044 | Los Angeles | California | 90033 | — |
| Local Institution - 0035 | Los Angeles | California | 90048 | — |
| Local Institution - 0067 | Stanford | California | 94305 | — |
| Local Institution - 0138 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0034 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0049 | Tampa | Florida | 33612 | — |
| Local Institution - 0068 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0038 | Indianapolis | Indiana | 46202 | — |
| Local Institution - 0042 | Iowa City | Iowa | 52242 | — |
| Local Institution - 0163 | Fairway | Kansas | 66205 | — |
| Local Institution - 0048 | Baltimore | Maryland | 21201 | — |
| Local Institution - 0004 | Baltimore | Maryland | 21287 | — |
| Local Institution - 0135 | Boston | Massachusetts | 02111 | — |
| Local Institution - 0110 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0161 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0173 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0046 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0043 | Detroit | Michigan | 48201 | — |
| Local Institution - 0036 | Buffalo | New York | 14263 | — |
| Local Institution - 0001 | New York | New York | 10065 | — |
| Local Institution - 0008 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0045 | Durham | North Carolina | 27710 | — |
| Local Institution - 0007 | Cleveland | Ohio | 44195 | — |
| Local Institution - 0164 | Columbus | Ohio | 43210 | — |
| Local Institution - 0039 | Portland | Oregon | 97239 | — |
| Local Institution - 0054 | Allentown | Pennsylvania | 18105 | — |
| Local Institution - 0005 | Philadelphia | Pennsylvania | 19111 | — |
| Local Institution - 0031 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 0055 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0159 | Chattanooga | Tennessee | 37403 | — |
| Local Institution - 0066 | Nashville | Tennessee | 37203 | — |
| Local Institution - 0056 | Dallas | Texas | 75246 | — |
| Local Institution - 0032 | Dallas | Texas | 75390-8852 | — |
| Local Institution - 0003 | Houston | Texas | 77030-4009 | — |
| Local Institution - 0041 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 152 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02231749, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02231749 live on ClinicalTrials.gov.